Linda Grais

Linda Grais Back to Board Former President and Chief Executive Officer, Ocera Therapeutics

Linda Grais, MD, JD was President, Chief Executive Officer and member of the Board of Directors of Ocera Therapeutics (OCRX), a biopharmaceutical company developing novel treatments for gastrointestinal and liver diseases, from 2012 until its acquisition by Mallinckrodt in December, 2017. Dr. Grais has extensive experience in the healthcare field as a physician, biotechnology entrepreneur and investor. Previously, she was a Managing Member at InterWest Partners, a venture capital firm investing in drug development and medical device companies. Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals (SGXP), which pioneered the integration of genomics with high-throughput protein structure determination to accelerate drug discovery. SGXP went public on NASDAQ and was acquired by Eli Lilly in 2006. Prior to founding SGX, Dr. Grais worked in the corporate practice at Wilson Sonsini Goodrich & Rosati, where she represented healthcare companies in venture financings, public offerings and strategic partnerships. Dr. Grais trained in Internal Medicine and Critical Care Medicine at Yale and the University of California, San Francisco, and was an Assistant Clinical Professor of Internal Medicine and Critical Care at UCSF.

Dr. Grais received a B.A. from Yale University, Magna Cum Laude and Phi Beta Kappa, an M.D. from Yale Medical School, and a J.D. from Stanford Law School. She has served on several advisory boards, including the Master’s Degree in Translational Medicine at UCSF, Yale Healthcare Advisory Board, and the Stanford Law School Board of Visitors. Dr. Grais currently serves on the Boards of Directors of Arca Biopharma, Inc. and PRA Health Sciences, Inc. She has received numerous honors, including the American Liver Foundation’s 2015 Salute to Excellence Award.